View Older Stories
-
Boston Scientific (BSX) 337K contracts trade, compared to its 90-day average volume of 17K contracts
-
RBC Capital on Boston Scientific (BSX): 'Lower WATCHMAN Outlook Drives Stock Down 13% Today'
-
Boston Scientific (BSX) PT Lowered to $74 at Leerink
-
Boston Scientific shares fall 10% on Watchman weakness, competitive pressures
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Raised to $87 at Leerink
-
Piper Sandler on Boston Scientific (BSX): 'The current pullback an attractive entry point'
-
Boston Scientific SEISMIQ 4CE catheter meets trial safety goals
-
Truist Securities Reiterates Buy Rating on Boston Scientific (BSX) amid buyback and third TAVR attempt
-
Pullback in this medical devices stock is overdone, according to Piper Sandler
-
Boston Scientific expands pacemaker recall to cover all ACCOLADE devices
-
Piper Sandler Reiterates Overweight Rating on Boston Scientific (BSX), 'recent pullback in shares is overdone'
-
Boston Scientific (BSX) PT Lowered to $96 at Barclays
-
Nephron Upgrades Boston Scientific (BSX) to Buy
-
Boston Scientific (BSX) PT Lowered to $85 at Truist Securities
-
Boston Scientific (BSX) PT Lowered to $84 at Goldman Sachs
-
Boston Scientific (BSX) PT Lowered to $71 at Canaccord
-
Boston Scientific (BSX) PT Lowered to $77 at Needham
-
Boston Scientific (BSX) PT Lowered to $100 at RBC Capital
-
Boston Scientific (BSX) PT Lowered to $100 at Jefferies
-
Boston Scientific (BSX) PT Lowered to $80 at BTIG
-
Boston Scientific (BSX) Tops Q1 EPS by 1c, Beats on Revenue; Offers FY26 EPS Guidance
-
Boston Scientific (BSX) call put ratio 1.5 calls to 1 put as share price down 1.9%
-
Boston Scientific (BSX) PT Lowered to $100 at Barclays
-
Boston Scientific (BSX) PT Lowered to $85 at Stifel
-
Q1 MedTech quarterly preview: BTIG
-
Boston Scientific (BSX) PT Lowered to $90 at Truist
-
Piper Sandler on BSX and MDT Following KOL Call
-
RBC Capital on Boston Scientific (BSX): 'We Are Bullish on the LT Thesis At Current Valuations'
-
UBS Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) call put ratio 1.3 calls to 1 put as share price down 9%
-
Raymond James downgrades Boston Scientific but long-term story remains intact
-
Truist Securities Reiterates Buy Rating on Boston Scientific (BSX)
-
RBC Capital on Boston Scientific (BSX): 'Results Point to Positive Uptake'
-
Boston Scientific (BSX) Reiterated at Buy by Stifel After CHAMPION-AF Read-Out
-
Boston Scientific receives FDA clearance for Asurys fluid management device
-
Raymond James Downgrades Boston Scientific (BSX) to Outperform
-
Bernstein Reiterates Outperform Rating on Boston Scientific (BSX)
-
Evercore ISI adds Boston Scientific (BSX) to TAP Outperform List
-
Stifel on Boston Scientific (BSX): 'this review adds to our optimism'
-
Boston Scientific (BSX) PT Lowered to $92 at Truist Securities
-
Jefferies on Boston Scientific (BSX): ICTx segment emerges as a double-digit growth engine
-
Piper Sandler's Key Takeaways From CRT 2026
-
Piper Sandler: 'When Will Things Turn in Med Tech and What Names to Own Now?'
-
TD Cowen on Boston Scientific (BSX): 'We See a Valuation Disconnect at Current Prices'
-
Boston Scientific (BSX) PT Lowered to $112 at Bernstein SocGen Group
-
Evercore ISI Removes Boston Scientific (BSX) from TAP List
-
Boston Scientific (BSX) PT Lowered to $115 but RBC Capital Sees Stock Reaction as a Buying Opportunity
-
Boston Scientific (BSX) PT Lowered to $97 at Needham
-
Oppenheimer Reiterates Outperform Rating on Boston Scientific (BSX)

